Personalis, Inc. (PSNL) is in Healthcare, Diagnostics & Research, based in United States, listed on NasdaqGM. Market cap 1.71B USD. 52-week range 4.96 to 18.89 USD. Data as of 2026-10-09.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor ...